Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Ketamina para el trastorno combinado de depresión y consumo de alcohol (KeDA)

14 de noviembre de 2026 actualizado por: Andreas Wahl Blomkvist, University Hospital of North Norway

Ketamina para el trastorno combinado de depresión y consumo de alcohol: un ensayo ciego, aleatorizado y controlado con placebo activo (el ensayo KeDA)

The goal of this clinical trial is to investigate the effects of ketamine, in combination with standard inpatient addiction therapy, for adults with depression and alcohol use disorder. After screening and enrollment, participants will undergo baseline assessments of depression, measures of alcohol use and craving, as well as neurocognitive function. Participants will then be randomized to either ketamine (intervention) or midazolam (control). All participants will be admitted for standard inpatient addiction therapy while receiving ketamine or midazolam. Measures on safety, depression and alcohol use disorder will be repeatedly assessed during and after treatment. Final follow-up assessment is scheduled 6 months after baseline assessment.

Descripción general del estudio

Descripción detallada

Depression and alcohol use disorder (AUD) often coexist and can create significant challenges for individuals seeking effective treatment. Traditional treatment approaches have shown limited success in addressing both conditions simultaneously. Ketamine has shown to have promising rapid antidepressant effects and a possible role in the treatment of substance use disorders. By targeting both depression and AUD simultaneously, ketamine has the potential to offer dual benefits, improving depressive symptoms while addressing alcohol cravings or consumption. Furthermore, rapid relief from depressive symptoms may enhance motivation for recovery, reduce the risk of relapse, and improve overall treatment engagement and outcomes. Although ketamine is generally considered safe when administered under medical supervision, the safety profile in individuals with comorbid depression and AUD needs further investigation. The overall objective of this study is to examine the safety and efficacy of ketamine on adults with depression and AUD that are admitted for standard inpatient addiction therapy.

The study will only include adults with at least moderate depression and alcohol use disorder as their primary substance use disorder that are admitted for inpatient addiction therapy. Participants that are unable to give informed consent or have contraindication(s) for ketamine will be excluded.

After screening and enrollment, participants will undergo baseline assessments with measures on depression (using Montgomery-Åsberg Depression Rating Scale (MADRS) and Beck Depression Inventory-II (BDI-II)), alcohol use (using Timeline Follow-Back method (TLFB)), alcohol craving (using Short version of Alcohol Craving Questionnaire (ACQ-Short) and Penn Alcohol Craving Scale (PACS)) and neurocognitive function (using Cambridge Neuropsychological Test Automated Battery (CANTAB)). Participants will then be randomized to intervention group or control group. The intervention group will receive ketamine as four single doses, given biweekly for two weeks. The control group will receive midazolam as active placebo. Participants will undergo several follow-up assessments after treatment (1-2 day(s), 1 week, 2 weeks and 4 weeks after treatment). Final follow-up assessment will be 6 months after baseline.

By using open questions and specific instruments for assessing adverse effects associated with ketamine (using modified version of Ketamine Side Effect Tool (mKSET)), the trial will assess the frequency, severity and duration of any adverse events and severe adverse events. All adverse events will be evaluated with regards to its causal relationship to ketamine. In addition, physician-assessed and patient-assessed tolerability will be registered. Changes in neurocognitive function from baseline will be assessed after treatment.

Changes in depression will be measured several times using rater-blinded MADRS-assessment and self-report instrument (BDI-II). Measures of alcohol use (TLFB), alcohol craving (ACQ-short and PACS), relapse risk and time until relapse will used as measures on alcohol use disorder following treatment. Several exploratory objectives will be examined, including changes in alcohol dependence severity (using Severity of Alcohol Dependence Questionnaire (SADQ)), changes in quality of life (using World Health Organizations brief quality of life questionnaire (WHOQOL-BREF)), changes in self-reported treatment effectiveness (using Treatment Effectiveness Assessment (TEA)) and changes in anxiety (using Generalized Anxiety Disorder scale (GAD-7)). Finally, data on the subjective experience of the treatment (using Ego Dissolution Inventory (EDI), Emotional Breakthrough Inventory (EBI) and Mystical Experience Questionnaire (MEQ30)) will be collected and used in a regression model with baseline measures to assess predictors of treatment response on measures of depression and AUD .

Tipo de estudio

Intervencionista

Inscripción (Estimado)

34

Fase

  • Fase 2
  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Ole K Grønli, Assoc Prof
  • Número de teléfono: +47 91713535
  • Correo electrónico: ole.k.gronli@unn.no

Ubicaciones de estudio

      • Moss, Noruega, 1535
        • Aún no reclutando
        • Department of Addiction Treatment, ØHT
        • Contacto:
        • Investigador principal:
          • Mina Piiksi Dahli, PhD, M.D.
      • Tromsø, Noruega
        • Reclutamiento
        • Department of Addiction, University Hospital of North Norway
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Please contact the project team for a full and detailed list of inclusion/exclusion criteria

Inclusion Criteria:

  • Currently abstinent from alcohol
  • At least moderate depression without psychotic features
  • Minimum Montgomery-Åsberg Depression Rating Scale (MADRS) of 20
  • Alcohol dependence
  • Admitted for inpatient addiction therapy at University Hospital of North Norway or Østfold Hospital Trust

Exclusion Criteria:

  • Intoxicated or in significant withdrawal from alcohol or drug use
  • Not able to give adequate informed consent
  • Current or past history of schizophrenia, schizophreniform disorder, paranoid delusional disorder, schizoaffective disorder
  • Current or historical diagnosis of schizophrenia in a first degree relative
  • Cardiovascular conditions: recent stroke (< 1 year from informed consent), recent myocardial infarction (< 1 year from informed consent), uncontrolled hypertension (>150/100 mm Hg) or recent arrhythmia (< 1 year from informed consent; clinically significant arrhythmia requiring treatment at hospital)
  • Liver (Child-Pughs Class C) or kidney (Creatinin clearance < 30 mL/min) failure
  • Heart failure (the New York Heart Association Functional Classification (NYHA) class III or IV)
  • Chronic respiratory failure (requiring long-term oxygen therapy (LTOT) and/or Global Initiative for Chronic Obstructive Lung Disease system (GOLD) stage 3 or higher)
  • Previous anaphylactic reaction to ketamine or midazolam
  • Illegal use of ketamine the last 6 months
  • Pregnancy or breastfeeding
  • Current or suspected increased intracranial pressure

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Intervention group

Ketamine, 0,8 mg/kg body weight, given as four single doses (biweekly for two weeks)

Four single-doses, given two times per week for two weeks Dose: 0,8 mg/kg body weight Route of administration: intravenous infusions over 40 minutes

Comparador activo: Control group

Midazolam, 0,8 mg/kg body weight, given as four single doses (biweekly for two weeks)

Four single-doses, given two times per week for two weeks Dose: 0,02 mg/kg body weight Route of administration: intravenous infusions over 40 minutes

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Depression
Periodo de tiempo: Within 3 days after final treatment session

Change from baseline using rater-blinded Montgomery-Åsberg Depression Rating Scale (MADRS) (range 0-60; higher score indicate worse outcome)

Within 3 days after final treatment session

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Alcohol craving tonic
Periodo de tiempo: Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session

Penn Alcohol Craving Scale (PACS) (range 0-30; higher score indicate worse outcome)

Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session
Alcohol craving phasic
Periodo de tiempo: Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session

Alcohol Craving Questionnaire - Short version (ACQ-short) (range 12-84; higher score indicate worse outcome)

Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session
Depression response/remission
Periodo de tiempo: Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session

Rates of response (50% or more reduction in MADRS from baseline) and remission (9 points or less in MADRS)

Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session
Relapse risk
Periodo de tiempo: From baseline until 6 months after baseline

Incidence of relapse in each group (defined as two or more consecutive heavy drinking days)

From baseline until 6 months after baseline
Time until relapse
Periodo de tiempo: From baseline until 3 and 6 months after baseline

Average time from final treatment session until relapse

From baseline until 3 and 6 months after baseline

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Duration of antidepressant effect (blinded-rater assessed)
Periodo de tiempo: From baseline until 6 months after baseline

Change in Montgomery-Åsberg Depression Rating Scale (MADRS) (range 0-60; higher score indicate worse outcome)

From baseline until 6 months after baseline
Duration of antidepressant effect (self-report)
Periodo de tiempo: From baseline until 6 months after baseline

Change in the Beck Depression Inventory-II (BDI-II) (Range 0-63; higher score indicate worse outcome)

From baseline until 6 months after baseline
Tolerability using the ketamine side effect tool (KSET)
Periodo de tiempo: Up to 1 month

Physician-reported tolerability of each treatment session (good, moderate and poor)

Up to 1 month
Tolerability using the ketamine side effect tool (KSET)
Periodo de tiempo: Up to 1 month

Patient-reported tolerability of each treatment session (good, moderate and poor)

Up to 1 month
Cambridge Neuropsychological Test Automated Battery (CANTAB): Stop Signal Task (SST); Spatial Working Memory (SWM) task; Intra-Extra Dimensional Shift (IED) task; Paired Associates Learning (PAL) task; Emotional Bias Task (EBT)
Periodo de tiempo: Within 3 days after final treatment session

Assess within- and between-group changes in neurocognitive function from baseline to within three days from the final treatment session: SST (Range 0-1000; Lower score indicate better outcome); SWM (Range: 2-14; Lower score indicates better outcome); IED (Range: 0-402; Lower score indicates better outcome); PAL (Range: 0-70; Lower score indicates better outcome); EBT (Range: 0-15; Higher score indicates better outcome (more happy))

Within 3 days after final treatment session
Adverse reaction frequency
Periodo de tiempo: Up to 6 months

Frequency of adverse reactions

Up to 6 months
Adverse reaction severity
Periodo de tiempo: Up to 6 months

Number of mild, moderate and severe adverse reactions

Up to 6 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Ole K Grønli, Assoc Prof, University Hospital of North Norway
  • Investigador principal: Andreas W Blomkvist, M.D., University Hospital of North Norway

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Enlaces Útiles

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

20 de enero de 2025

Finalización primaria (Estimado)

1 de julio de 2028

Finalización del estudio (Estimado)

1 de julio de 2028

Fechas de registro del estudio

Enviado por primera vez

1 de julio de 2023

Primero enviado que cumplió con los criterios de control de calidad

16 de octubre de 2023

Publicado por primera vez (Actual)

19 de octubre de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

14 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant data will not be shared with external researchers because the participant information and consent form limits research access to those formally affiliated with the KeDA trial.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir